Aktie CARDIUM THERAPEUTICS INC
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Cardium Therapeutics Inc Nyse

Aktien

US1419161062

Schlusskurs Nyse
Andere Börsenplätze
- USD - Intraday Chart für Cardium Therapeutics Inc
2022 Gene Biotherapeutics, Inc. Wirtschaftsprüfer äußert Zweifel an der Unternehmensfortführung (Going Concern) CI
2021 Gene Biotherapeutics, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2020 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
GENE BIOTHERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
GENE BIOTHERAPEUTICS : Changes in Registrant's Certifying Accountant (form 8-K/A)
GENE BIOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant (form 8-K)
GENE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
Gene Biotherapeutics, Inc. Announces Resignation of Murray H. Hutchison from the Board
GENE BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Gene Biotherapeutics Inc. Enters into an Agreement with Fujifilm Diosynth Biotechnologies to Manufacture the Generx Angiogenic Gene Therapy Product
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
GENE BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
Gene Biotherapeutics, Inc. Announces Management Changes
Gene Biotherapeutics, Inc. Appoints James L. Grainer as Chief Financial Officer
Gene Biotherapeutics, Inc. announced that it has received $1.7 million in funding from Nostrum Pharmaceuticals LLC
Gene Biotherapeutics Inc. Announces Retirement of Gerald J. Lewis from its Board of Directors
Gene Biotherapeutics Inc. Enters into an Agreement with the Olaregen Therapeutix Inc
Gene Biotherapeutics Mulls Acquisitions
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A12C67 Aktie
  4. Aktie
  5. Nachrichten Cardium Therapeutics Inc
  6. Andere Sprachen